S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
In a recent transaction, Neal Franklin Fowler, a director at Emergent BioSolutions Inc. (NYSE:EBS), sold a significant portion of the company’s common stock. According to a filing with the Securities and Exchange Commission, Fowler sold 35,000 shares on March 12, 2025. The shares were sold at an average price of $5.83, within a price range of $5.81 to $5.89, bringing the total transaction value to approximately $204,050. The transaction occurs as InvestingPro data shows the stock trading near oversold levels, with shares up over 160% in the past year despite recent volatility. According to InvestingPro’s Fair Value analysis, the stock appears slightly undervalued at current levels.
Following this sale, Fowler retains ownership of 101,100 shares of Emergent BioSolutions. The sale was executed directly by Fowler, and the company has maintained records of the transaction details, which are available upon request. With a market capitalization of $337 million and a strong current ratio of 3.69, InvestingPro analysis reveals 8 additional key insights about EBS’s financial health and market position. Access the complete Pro Research Report for deeper analysis of what matters most about this stock.
In other recent news, Emergent BioSolutions reported its fourth-quarter financial results, revealing a revenue of $194.7 million, which fell short of the consensus forecast of $243.33 million. Despite this revenue miss, the company posted adjusted earnings per share of $0.05, surpassing the analyst estimate of a $0.41 loss. Total (EPA:TTEF) revenue saw a 30% decline year-over-year, largely due to a significant drop in sales of NARCAN nasal spray and anthrax medical countermeasures. However, smallpox countermeasure sales surged by 565%, driven by increased international orders for the ACAM2000 vaccine. Emergent BioSolutions has projected its 2025 revenue to range between $750 million and $850 million, with expectations of improved gross margins. The company also anticipates achieving a cash flow-positive status, with a projected net income of $16 million to $66 million. H.C. Wainwright maintained a Buy rating on Emergent BioSolutions, setting a price target of $15, despite the mixed financial results. Additionally, Emergent BioSolutions announced the sale of its Baltimore-Bayview manufacturing facility to Syngene International for $36.5 million, as part of its strategic transformation plan.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.